Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales exceeded the year-earlier period across all business areas. Contributions came from capacity expansions in China and Malaysia in Mobility & Imaging, firm semiconductor market conditions in Fine Chemicals, and pharmaceutical market penetration and increased domestic sales and exports in the agro business in Life Sciences. Ordinary income increased mainly due to foreign exchange gains and other factors, while net income attributable to owners of the parent increased mainly due to gains on the sale of investment securities and other factors.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥67,402 million (YoY +23.1%) |
| Operating profit | ¥6,740 million (YoY +54.3%) |
| Ordinary income | ¥7,390 million (YoY +81.7%) |
| Profit attributable to owners of the parent | ¥6,081 million (YoY +41.7%) |
| Net income per share | ¥41.08 |
| Equity ratio | End of the current fiscal period 67.3 / End of previous period 70 |
| Total assets | ¥419,884 million |
| Net assets | ¥283,669 million |
| Full-year earnings forecast | Net Sales ¥270,900 million (YoY +12.0%) / Operating profit ¥27,300 million (YoY +21.6%) / Ordinary income ¥27,000 million (YoY +6.0%) / Profit attributable to owners of the parent ¥22,900 million (YoY -7.1%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥270,900 million / Operating profit Not disclosed → ¥27,300 million / Ordinary income Not disclosed → ¥27,000 million / Profit attributable to owners of the parent Not disclosed → ¥22,900 million |
| Annual Dividend Forecast | ¥66 → ¥66（0.0%） |
| Segment revenue | Mobility & Imaging business area ¥26,927 million (YoY +20.3%), Fine Chemicals business area ¥20,554 million (YoY +23.0%), Life Sciences business area ¥19,920 million (YoY +27.2%) |
| Segment profit | Mobility & Imaging business area ¥3,392 million (YoY +43.9%), Fine Chemicals business area ¥3,324 million (YoY +33.2%), Life Sciences business area ¥2,184 million (YoY +17.3%) |
| Depreciation and amortization | ¥3,453 million |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥11 million, Gain on sale of investment securities ¥1,725 million, Government subsidies ¥98 million / Extraordinary loss Losses on disposal of fixed assets ¥197 million, Loss on reduction of fixed assets ¥96 million, Special retirement payments ¥40 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes Yes / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person For securities analysts and institutional investors |
| Issued Shares at Period-End | 148,700,000 shares |
| Treasury Shares at Period-End | 1,449,578 shares |
| Factors Behind Changes in Business Performance | Net sales exceeded the year-earlier period across all business areas. Contributions came from capacity expansions in China and Malaysia in Mobility & Imaging, firm semiconductor market conditions in Fine Chemicals, and pharmaceutical market penetration and increased domestic sales and exports in the agro business in Life Sciences. Ordinary income increased mainly due to foreign exchange gains and other factors, while net income attributable to owners of the parent increased mainly due to gains on the sale of investment securities and other factors. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased across all business areas. In Mobility & Imaging, sales increased as capacity expansions in China and Malaysia proved effective. In Fine Chemicals, the semiconductor market remained firm. In Life Sciences, pharmaceutical market penetration and domestic sales and exports in the agro business increased. Ordinary income rose mainly due to foreign exchange gains and other factors, while net income attributable to owners of the parent increased mainly due to gains on the sale of investment securities and other factors.